{
    "clinical_study": {
        "@rank": "136195", 
        "acronym": "ATLL-HR-01", 
        "arm_group": [
            {
                "arm_group_label": "ZPI", 
                "description": "Zidovudine 1000mg/day : Retrovir\u00ae 250mg/day) PegINF (Pegasys\u00ae) 180\u03bcg x1 injection/week"
            }, 
            {
                "arm_group_label": "ZPI+CHOP-21", 
                "description": "Zidovudine 1000mg/day : Retrovir\u00ae 250mg/day) PegINF (Pegasys\u00ae) 180\u03bcg x1 injection/week\nCHOP-21 Day1 = day 21 (3 cycles)\nDay 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day  PO.\nday 2-Day 5 Prednisone\n1mg/kg/day PO."
            }, 
            {
                "arm_group_label": "ZPI +DHAP-21", 
                "description": "Zidovudine 1000mg/day : Retrovir\u00ae 250mg/day) PegINF (Pegasys\u00ae) 180\u03bcg x1 injection/week\nDHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients are recruited at diagnosis or at relapse of ATLL-HR in French Caribbean islands and\n      Guyana. They all receive Zidovudine and Pegylated Interferon (ZPI). For patients younger\n      than 65 years old, an allogeneic donor is searching out. Patients included at relapse and\n      with lymphoma clinico-biological subtype also receive chemotherapy (CT). Responses are\n      assessed during ZPI+/-CT and eligible patients (depending on age, comorbidities and response\n      criteria) receive allogeneic transplant. Patient follow-up is planned for 3 years old"
        }, 
        "brief_title": "High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "T-cell Lymphoma", 
            "Leukaemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia-Lymphoma, Adult T-Cell", 
                "Lymphoma", 
                "Lymphoma, T-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient >18 years old and \u2264 75 years old, with ATLL-HR who signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing women are not eligible; neither are women of childbearing\n             potential unless using effective contraception as determined by the patient's\n             physician."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Populations of French Caribbean Islands and Guyana with ATLL-HR. ."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941680", 
            "org_study_id": "13/B/04", 
            "secondary_id": "2013-A00327-38"
        }, 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 10, 2013", 
        "location": [
            {
                "contact": {
                    "email": "tawfik.chalabi@chu-guadeloupe.fr", 
                    "last_name": "Tawfik CHALABI, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pointe \u00e0 Pitre", 
                        "country": "Guadeloupe"
                    }, 
                    "name": "CHU Pinte\u00e0 Pitre/Abymes"
                }, 
                "investigator": {
                    "last_name": "Tawfik CHALABI, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Jean-Come.Meniane@chu-fortdefrance.fr", 
                    "last_name": "Jean-C\u00f4me MENIANE"
                }, 
                "contact_backup": {
                    "email": "mickaelle.rose@chu-fortdefrance.fr", 
                    "last_name": "Micka\u00eblle ROSE", 
                    "phone": "+596596592623"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort de France", 
                        "country": "Martinique"
                    }, 
                    "name": "CHU de Martinique"
                }, 
                "investigator": {
                    "last_name": "Jean-C\u00f4me MENIANE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Guadeloupe", 
                "Martinique"
            ]
        }, 
        "number_of_groups": "3", 
        "official_title": "Observational Prospective Study, Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon +/-Polychemotherapy in High Risk Adult-T-cell Lymphoma/Leukaemia (T-cell Lymphoma/Leukaemia) Followed by Allogeneic Transplant Among Eligible Patients Younger Than 65 Years Old", 
        "overall_contact": {
            "email": "Jean-Come.Meniane@chu-fortdefrance.fr", 
            "last_name": "Jean-C\u00f4me MENIANE, MD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with relapse", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941680"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The titrations of genes are performed at month 12, month 24 and month 36", 
            "measure": "Evidence of presence of gene expression of Tax and HBZ confirmed by Rt-PCR", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Centre Hospitalier Universitaire de Fort-de-France", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de Fort-de-France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Ecologic or Community, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}